Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LDP, JPMA Exchange Opinions on How to Promote Clinical Trials in Japan
May 17, 2010
- Korosho, METI Set Up Joint Task Force to Promote New Growth Strategy
May 17, 2010
- Collategene Achieves Primary Endpoint in PIII Trial: AnGes MG
May 17, 2010
- PMDA Should Continue, Even Expand Its Activities: Screening by GRU
May 17, 2010
- Asahi Kasei's AT-877 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- PMDA to Relax Working Regulations for Former Company Employees
May 17, 2010
- Hisamitsu's HKT-500 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- Five NIBIO Projects Screened by GRU
May 17, 2010
- NIBIO Identifies Protein Related to Colon, Esophageal Cancer
May 17, 2010
- Takeda Obtains Approval for 5 Products, Including 1st In-house Product in 11 Years
May 3, 2010
- 6 Drugs, Including Orencia, Recommended for Approval
May 3, 2010
- Approval for Greater Strength Recommended for Pasil/Pazucross
May 3, 2010
- ASKA Aims at Sales of ¥50 Bil. in FY2012
May 3, 2010
- PMDA Must Accelerate Hiring of Reviewers: Mr Osa
May 3, 2010
- Shionogi, Eli Lilly Japan to Comarket Cymbalta
May 3, 2010
- PMDA, NIBIO to Be Targeted in 2nd Round of Screening
May 3, 2010
- Novartis Confident of Being Able to Differentiate Equa from Other DPP-4 Inhibitors
May 3, 2010
- PMDA's Reform Proposal Found Insufficient by Majority of Screeners: Internal Screening
May 3, 2010
- NEW PRODUCT
May 3, 2010
- MTPC Voluntarily Refrains from Promoting 7 Products Exempted from Sanction
May 3, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…